{"analyses":[{"ciLowerLimit":"0.2270","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.3524","estimateComment":"Hazard Ratio based on stratified Cox proportional hazards model with stratification factors: hormone receptor status, prior treatment with pertuzumab, and history of visceral disease, as defined by the IXRS.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.000001","pValueComment":"Stratified Log-rank p-value.","paramType":"Hazard Ratio (HR)","paramValue":"0.2828","statisticalComment":"p value based on log-rank stratified by hormone receptor status, prior treatment with pertuzumab, and history of visceral disease, as defined by IXRS","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.3","upperLimit":"19.6","value":"16.7"},{"groupId":"OG001","lowerLimit":"4.4","upperLimit":"7.0","value":"5.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"406"},{"groupId":"OG001","value":"202"}],"units":"Participants"}],"description":"Progression-free survival (PFS) by investigator assessment was defined as the time from the date of randomization to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), who received T-DXd as a sterile intravenous (IV) solution at a dose of 5.4 mg/kg every 3 weeks (Q3W).","id":"OG000","title":"Trastuzumab Deruxtecan (T-DXd)"},{"description":"Participants with HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), who received investigator's choice treatment, Trastuzumab/Capecitabine or Lapatinib/Capecitabine.","id":"OG001","title":"Treatment of Investigator's/Physician's Choice (TPC)"}],"paramType":"MEDIAN","populationDescription":"Progression-free survival (PFS) was assessed in the Full Analysis Set at data cut-off date of 30 Jun 2022.","reportingStatus":"POSTED","timeFrame":"Up to 46 months","title":"Progression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine","type":"SECONDARY","unitOfMeasure":"months"}